The earnings call highlighted strong financial performance with significant revenue growth and stabilization of the company's financial position. Despite the positive developments, challenges such as the impact of Germany's Eurotransplant program pause and company restructuring were noted. Overall, the positive aspects outweigh the challenges, leading to a positive sentiment.

Company Guidance -

Q3 2025

During the Hansa Biopharma Q2 2025 earnings call, the company provided guidance on several key fronts. The CEO, Renee Aguiar-Lucander, highlighted a successful capital raise of SEK 232 million, ensuring a cash runway into early Q2 2026. The company also restructured its debt with NovaQuest, converting $14.8 million of debt into equity, with remaining payments scheduled between 2027 and 2029. Hansa reported a significant 76% year-over-year increase in IDEFIRIX sales revenue for Q2 2025, totaling SEK 47.9 million, and a 52% increase for the first half of the year, reaching SEK 113.5 million. Total revenues for the first half of 2025 rose by 27% compared to the same period in 2024. Operationally, the company completed enrollment for the Phase III PAES study in kidney transplantation, with a data readout expected in mid-2026, and saw positive results from the 15-HMedIdeS-09 Phase II study in Guillain-Barre syndrome. Hansa anticipates key data readouts for the ConfIdeS trial in kidney transplantation and the GOOD-IDES-02 trial in anti-GBM later in 2025.

Significant Financial Performance and Revenue Growth

IDEFIRIX sales revenues for Q2 were SEK 47.9 million, representing a 76% increase compared to Q2 2024. Total revenue in the first half of 2025 increased by 27% compared to the first half of 2024.

Stabilized Financial Position

The company successfully raised SEK 232 million and restructured existing debt, ensuring a cash runway into Q2 2026.

Expansion and Market Approvals

IDEFIRIX is now reimbursed in 20 countries, including Australia and Switzerland, and guidelines in nine countries support its use as a desensitization strategy.

Pipeline Progress

Completion of enrollment in the Phase III PAES study in kidney transplantation and positive results from the 15-HMedIdeS-09 Phase II study in Guillain-Barre syndrome.

Hansa Biopharma AB (SE:HNSA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

SE:HNSA Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 23, 2025	2025 (Q3)	-1.41 / -	-1.53	―	―	―
Jul 17, 2025	2025 (Q2)	-1.66 / -2.53	-3.3	23.33% (+0.77)	―	―
Apr 24, 2025	2025 (Q1)	-2.67 / -0.55	-4.15	86.75% (+3.60)	―	―
Feb 06, 2025	2024 (Q4)	-1.98 / -4.08	-2.4	-70.00% (-1.68)	―	―
Oct 17, 2024	2024 (Q3)	-2.42 / -1.53	-4.78	67.99% (+3.25)	―	―
Jul 18, 2024	2024 (Q2)	-2.78 / -3.30	-4.79	31.11% (+1.49)	―	―
Apr 18, 2024	2024 (Q1)	-3.46 / -4.15	-3.92	-5.87% (-0.23)	―	―
Feb 02, 2024	2023 (Q4)	-3.72 / -2.40	-3.19	24.76% (+0.79)	―	―
Oct 26, 2023	2023 (Q3)	-3.98 / -4.78	-3.45	-38.55% (-1.33)	―	―
Jul 20, 2023	2023 (Q2)	-3.54 / -4.79	-1.91	-150.79% (-2.88)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

SE:HNSA Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 17, 2025	kr25.94	kr27.90	+7.56%
Apr 24, 2025	kr22.30	kr23.68	+6.19%
Feb 06, 2025	kr33.62	kr27.10	-19.39%
Oct 17, 2024	kr40.16	kr41.28	+2.79%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Hansa Biopharma AB (SE:HNSA) report earnings?

Hansa Biopharma AB (SE:HNSA) is schdueled to report earning on Oct 23, 2025, Before Open (Confirmed).

What is Hansa Biopharma AB (SE:HNSA) earnings time?

Hansa Biopharma AB (SE:HNSA) earnings time is at Oct 23, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is the P/E ratio of Hansa Biopharma AB stock?

The P/E ratio of Hansa Biopharma AB is N/A.

What is SE:HNSA EPS forecast?

SE:HNSA EPS forecast for the fiscal quarter 2025 (Q3) is -1.41.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing